Recurrent Ovarian Germ Cell Tumor Completed Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0029793 (Recurrent Ovarian Germ Cell Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00060372Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerTreatment